Tumor-associated antigen-Major Histocompatibility Complex class I complex on autologous dendritic cells (TAA-MHC I-DC)

The Tumor-associated antigen-Major Histocompatibility Complex (MHC) class I complex on autologous dendritic cells is a critical immunological assembly used in cancer immunotherapy. Dendritic cells are harvested from a patient and loaded with specific tumor-associated antigens (TAAs) to create this complex ex vivo (National Cancer Institute, 2023). These cells then process the antigens and present them on their surface via MHC class I molecules, which are essential for recognition by the adaptive immune system. The primary biological function of this complex is to prime and activate CD8+ cytotoxic T lymphocytes (CTLs), which are the main effectors of the anti-tumor immune response (PubMed, PMID: 30247715). Once re-infused into the patient, these activated T cells can identify and destroy tumor cells that express the same TAA-MHC I signature. This target is the foundation for dendritic cell vaccines, such as the FDA-approved Sipuleucel-T for prostate cancer (FDA, 2010). Clinical efficacy depends on the successful migration of these dendritic cells to lymph nodes and the subsequent robust expansion of antigen-specific T cells. Challenges associated with this target include tumor-mediated immune evasion, such as the downregulation of MHC molecules, and the risk of autoimmunity if the antigens are not strictly tumor-specific (Nature Reviews Cancer, 2021).

Other names

Autologous dendritic cell vaccineTAA-loaded dendritic cellsMHC class I-restricted tumor antigen presentationDC-based immunotherapyAntigen-presenting cell-based vaccine

Dendritic cells process and present tumor-associated antigens on MHC class I molecules to prime and activate CD8+ cytotoxic T lymphocytes, which then target and eliminate tumor cells expressing those specific antigens (PubMed, PMID: 30247715).